Clinical trials: Visual Function
Dry Eye
Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease
This is a phase 3 study to evaluate the safety and efficacy of OmegaD softgels for the treatment of dry eye disease. A daily dose of 2 OmegaD softgels dosed orally BID will be compared to 2 placebo softgels (mineral oil ) dosed…
- Trial name
- NCT04181593
- Testing
- Omega 3 fatty acid
- Where
- 14 sites in United States
- Volunteers
- 322 people
- Sponsor
- OmegaD LLC
Glaucoma, Angle-Closure
Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients
This study will evaluate the safety and efficacy of patients switched from latanoprost monotherapy to a combination therapy of latanoprost with COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) for…
- Trial name
- NCT01151904
- Testing
- brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution, latanoprost
- Where
- Thailand
- Volunteers
- 17 people
- Sponsor
- Allergan
Inflammation
Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery
This is a multicenter, double-masked, randomized, vehicle-controlled, parallel-comparison study conducted at sites in the United States (US) in subjects undergoing routine unilateral cataract extraction and lens replacement…
- Trial name
- NCT06164743
- Testing
- VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Vehicle
- Where
- 10 sites in United States
- Volunteers
- 91 people
- Sponsor
- VivaVision Biotech, Inc
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice.
- Trial name
- NCT01853085
- Testing
- Bimatoprost Ophthalmic Solution
- Where
- Germany
- Volunteers
- 1,830 people
- Sponsor
- Allergan
Allergic Rhinitis, Seasonal Allergic Rhinitis
Assessment of Fluticasone Propionate on Ocular Allergy Symptoms
This study is designed to investigate the efficacy of fluticasone propionate (FP) on ocular symptoms associated with allergic rhinitis (AR).
- Trial name
- NCT01817790
- Testing
- Fluticasone propionate
- Where
- United States
- Volunteers
- 626 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Visual Acuity
Evaluation of Multifocal Contact Lens Designs With and Without an HEV Blocker on Visual Function
This is a single-masked, bilateral, controlled, randomized, 2x2 crossover, non-dispensing clinical trial to characterize the effects of an HEV-Blocker on several measures of visual function in a presbyopic population.
- Trial name
- NCT04995055
- Testing
- JJVC Investigational Multifocal Contact Lens TEST Lens, ACUVUE® OASYS Multifocal
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
Phase III study to compare the safety and efficacy of intraocular implants containing Travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (Timolol) in reducing elevated intraocular pressure…
- Trial name
- NCT03868124
- Testing
- G2-TR intraocular implant containing travoprost
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- Glaukos Corporation
Primary Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
This is a Phase 3 study to evaluate the safety and efficacy of T-2345 dosed to one of both eyes once daily for 84 days compared to Xalatan dosed to one of both eyes once daily for 84 days in patients with elevated eye pressure.
- Trial name
- NCT02059278
- Testing
- T-2345, Xalatan
- Where
- United States
- Volunteers
- 335 people
- Sponsor
- Nephron Pharmaceuticals Corporation
Glaucoma, Open-Angle
Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy.
- Trial name
- NCT00693485
- Testing
- 400 ug Brimonidine Implant, 200 ug Brimonidine Implant
- Where
- 2 sites in United States, Israel
- Volunteers
- 70 people
- Sponsor
- Allergan
Progressive Supranuclear Palsy
Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
The clinical syndrome of PSP responds poorly to all available forms of therapy used in Parkinson's Disease (PD). Currently, no effective treatment exists.
- Trial name
- NCT00382824
- Testing
- Coenzyme Q10
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- Lahey Clinic
Ocular Discomfort
A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery
The primary objective of this exploratory study is to assess preliminary efficacy and safety of rhNGF when administered as eye drops to patients after cataract and refractive surgery.
- Trial name
- NCT03035864
- Testing
- rhNGF, Vehicle
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Dompé Farmaceutici S.p.A
Non-24-Hour Sleep-Wake Disorder
Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder
The purpose of this study is to evaluate the efficacy and safety of a six month double-mask treatment of tasimelteon or placebo in male and female subjects with Non-24-Hour Sleep-Wake Disorder
- Trial name
- NCT01163032
- Testing
- tasimelteon
- Where
- 28 sites in United States, Germany
- Volunteers
- 136 people
- Sponsor
- Vanda Pharmaceuticals
Dry Eye
The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface
This study will test that hypothesis that topical administration of the FDA approved immunomodulatory agent cyclosporin A emulsion will minimize irritation and ocular surface disease that results from a short term low humidity…
- Trial name
- CsA (NCT02199964)
- Testing
- Cyclosporin 0.05% emulsion, Endura, Refresh artificial tears
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Baylor College of Medicine
Open-Angle Glaucoma, Ocular Hypertension
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
In participants with a diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT), the primary objective is to demonstrate that the mean IOP reduction after 3 months of treatment with BOL-303259-X once daily (QD) is…
- Trial name
- LUNAR (NCT01749930)
- Testing
- BOL-303259-X, Timolol
- Where
- United States
- Volunteers
- 420 people
- Sponsor
- Bausch & Lomb Incorporated
Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to…
- Trial name
- Brilliance (NCT01922102)
- Testing
- Ranibizumab 0.5mg, Ranibizumab 0.5 mg, Verteporfin PDT
- Where
- 47 sites in China, Hong Kong and 4 more
- Volunteers
- 457 people
- Sponsor
- Novartis Pharmaceuticals
Glaucoma, Ocular Hypertension
A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension
This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P)…
- Trial name
- NCT01525173
- Testing
- 0.1% brimonidine tartrate ophthalmic solution, 0.01% bimatoprost ophthalmic solution, 0.2% hypromellose lubricant eye drops
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Allergan
Refractive Errors
Clinical Performance of a Silicone Hydrogel Contact Lens Following One Night of Extended Wear
The purpose of this clinical study is to evaluate the on-eye performance of an investigational soft contact lens compared to a commercially available soft contact lens following 1 night of extended wear.
- Trial name
- NCT03560141
- Testing
- LID011121 contact lens, Comfilcon A contact lens
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alcon Research
Ocular Hypertension
Effect of Alternate Therapies on Intraocular Pressure in Ocular Hypertension
The purpose of this study is to evaluate the effect of complementary and alternative therapies, specifically alternate nostril breathing and foot reflexology, on intraocular pressure in patients with ocular hypertension.
- Trial name
- NCT02993445
- Testing
- Alternate Nostril Breathing, Foot Reflexology
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Temple University
Ocular Physiology
Feasibility Evaluation of Daily Disposable Toric Soft Contact Lenses Manufactured With an Alternative Hydration Process
This is a bilateral wear, dispensing, randomized, controlled, double-masked, 2-sequence × 2-period crossover study to evaluate ocular physiology following approximately one week of contact lens wear.
- Trial name
- NCT05427539
- Testing
- TEST LENS, CONTROL LENS
- Where
- 6 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Glaucoma, Ocular Hypertension
Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
The purpose of this study was to assess the safety and describe the steady-state plasma pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation) following a once daily administration for 7 days in…
- Trial name
- NCT01658839
- Testing
- Travoprost ophthalmic solution, 0.004% (new formulation)
- Volunteers
- 25 people
- Sponsor
- Alcon Research